Antimicrobial Activities of BMY-28142, Cefbuperazone, and Cefpiramide Compared with Those of Other Cephalosporins

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 1984 Oct 1

PMID 6549120

Citations 19

Authors

N J Khan

J A Bihl

R F Schell

J L LeFrock

S J Weber

Affiliations

Soon will be listed here.

Abstract

The antimicrobial activities of BMY-28142, cefbuperazone (BMY-25182; formerly T-1982), and cefpiramide (WY-44635; formerly SM-1652) were compared with those of cefmenoxime, cefoperazone, cefotaxime, ceftizoxime, and moxalactam. BMY-28142 was the most active cephalosporin against the majority of aerobic and facultatively anaerobic microorganisms studied. Its spectrum of activity was very similar to that of cefotaxime. However, BMY-28142, cefbuperazone, cefmenoxime, cefotaxime, ceftizoxime, and moxalactam were equivalent in activity and rate of killing against members of the family Enterobacteriaceae. Cefpiramide was considerably less active than the other cephalosporins against the Enterobacteriaceae.

Citing Articles

The Chemical Relationship Among Beta-Lactam Antibiotics and Potential Impacts on Reactivity and Decomposition.

Turner J, Muraoka A, Bedenbaugh M, Childress B, Pernot L, Wiencek M Front Microbiol. 2022; 13:807955.

PMID: 35401470 PMC: 8988990. DOI: 10.3389/fmicb.2022.807955.

Cefepime clinical pharmacokinetics.

Okamoto M, Nakahiro R, Chin A, Bedikian A Clin Pharmacokinet. 1993; 25(2):88-102.

PMID: 8403741 DOI: 10.2165/00003088-199325020-00002.

Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Barradell L, Bryson H Drugs. 1994; 47(3):471-505.

PMID: 7514976 DOI: 10.2165/00003495-199447030-00007.

Respiratory superinfections after the use of third-generation cephem antibiotics.

Saito A, Mori K, Shigeno Y, Yamaguchi K, Hara K Infection. 1985; 13 Suppl 1:S89-95.

PMID: 4055061 DOI: 10.1007/BF01644226.

Interpretive standards of cefbuperazone disk diffusion susceptibility tests.

Barry A, Jones R, Thornsberry C Eur J Clin Microbiol. 1985; 4(2):144-5.

PMID: 4006934 DOI: 10.1007/BF02013585.

References

Garzone P, Lyon J, Yu V . Third-generation and investigational cephalosporins: I. Structure-activity relationships and pharmacokinetic review. Drug Intell Clin Pharm. 1983; 17(7-8):507-15. DOI: 10.1177/106002808301700703. View

Pfaller M, Niles A, Murray P . In vitro antibacterial activity of cefpiramide. Antimicrob Agents Chemother. 1984; 25(3):368-72. PMC: 185520. DOI: 10.1128/AAC.25.3.368. View

Lang S, Edwards D, Durack D . Comparison of cefoperazone, cefotaxime, and moxalactam (LY127935) against aerobic gram-negative bacilli. Antimicrob Agents Chemother. 1980; 17(3):488-93. PMC: 283815. DOI: 10.1128/AAC.17.3.488. View

Kurtz T, Winston D, Hindler J, Young L, HEWITT W, Martin W . Comparative in vitro activity of moxalactam, cefotaxime, cefoperazone, piperacillin, and aminoglycosides against gram-negative bacilli. Antimicrob Agents Chemother. 1980; 18(4):645-8. PMC: 284064. DOI: 10.1128/AAC.18.4.645. View

Bodey G, Fainstein V, Hinkle A . Comparative in vitro study in new cephalosporins. Antimicrob Agents Chemother. 1981; 20(2):226-30. PMC: 181667. DOI: 10.1128/AAC.20.2.226. View

Neu H . The new beta-lactamase-stable cephalosporins. Ann Intern Med. 1982; 97(3):408-19. DOI: 10.7326/0003-4819-97-3-408. View

Kato M, Inoue M, Mitsuhashi S . Antibacterial activities of SM-1652 compared with those of other broad-spectrum cephalosporins. Antimicrob Agents Chemother. 1982; 22(5):721-7. PMC: 185652. DOI: 10.1128/AAC.22.5.721. View

Tai M, Fukuoka Y, Yotsuji A, Kumano K, Takahata M, Mikami H . In vitro and in vivo antibacterial activity of T-1982, a new semisynthetic cephamycin antibiotic. Antimicrob Agents Chemother. 1982; 22(5):728-34. PMC: 185653. DOI: 10.1128/AAC.22.5.728. View

Fukasawa M, Noguchi H, Okuda T, Komatsu T, Yano K . In vitro antibacterial activity of SM-1652, a new broad-spectrum cephalosporin with antipseudomonal activity. Antimicrob Agents Chemother. 1983; 23(2):195-200. PMC: 186021. DOI: 10.1128/AAC.23.2.195. View

10.

LeFrock J, Prince R, Leff R . Mechanism of action, antimicrobial activity, pharmacology, adverse effects, and clinical efficacy of cefotaxime. Pharmacotherapy. 1982; 2(4):174-84. DOI: 10.1002/j.1875-9114.1982.tb03185.x. View

11.

Schell R, Smith B, LeFrock J, Francisco M . Antimicrobial activity of cefmenoxime compared with those of other cephalosporins. Antimicrob Agents Chemother. 1983; 23(5):774-7. PMC: 184814. DOI: 10.1128/AAC.23.5.774. View

12.

Garzone P, Lyon J, Yu V . Third-generation and investigational cephalosporins: II. Microbiologic review and clinical summaries. Drug Intell Clin Pharm. 1983; 17(9):615-22. DOI: 10.1177/106002808301700901. View

13.

Imasaki H, Enjoji Y, Matsui H, Kawai R, Kawamura S, Okuda T . Metabolic fate of [14C]SM-1652, a new antipseudomonal cephalosporin, after parenteral administration to rats. Antimicrob Agents Chemother. 1983; 24(1):42-7. PMC: 185102. DOI: 10.1128/AAC.24.1.42. View

14.

Seibert G, Limbert M, Winkler I, Dick T . The Antibacterial activity in vitro and beta-lactamase stability of the new cephalosporin HR 810 in comparison with five other cephalosporins and two aminoglycosides. Infection. 1983; 11(5):275-9. DOI: 10.1007/BF01641262. View

15.

Schell R, LeFrock J, Smith B, Francisco M . In vitro antimicrobial activity of ceftizoxime. Chemotherapy. 1983; 29(6):408-14. DOI: 10.1159/000238228. View

16.

Congeni B . Comparison of ceftriaxone and traditional therapy of bacterial meningitis. Antimicrob Agents Chemother. 1984; 25(1):40-4. PMC: 185431. DOI: 10.1128/AAC.25.1.40. View

17.

Wexler H, Carter W, Harris B, Finegold S . Comparative in vitro activities of cefpiramide and apalcillin against anaerobic bacteria. Antimicrob Agents Chemother. 1984; 25(2):162-4. PMC: 185465. DOI: 10.1128/AAC.25.2.162. View

18.

Smith B, LeFrock J, Carr B . Cefmenoxime penetration into gallbladder bile and tissue. Antimicrob Agents Chemother. 1983; 23(6):941-3. PMC: 185014. DOI: 10.1128/AAC.23.6.941. View